Diana Bockus - NGM Biopharmaceutica Head Development
| NGMDelisted Stock | USD 2.50 0.14 5.30% |
Executive
Diana Bockus is Head Development of NGM Biopharmaceuticals
| Phone | 650 243 5555 |
| Web | https://www.ngmbio.com |
NGM Biopharmaceutica Management Efficiency
The company has Return on Asset of (0.3846) % which means that on every $100 spent on assets, it lost $0.3846. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6976) %, meaning that it generated no profit with money invested by stockholders. NGM Biopharmaceutica's management efficiency ratios could be used to measure how well NGM Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.NGM Biopharmaceuticals has 5.38 M in debt with debt to equity (D/E) ratio of 0.03, which may show that the company is not taking advantage of profits from borrowing. NGM Biopharmaceuticals has a current ratio of 7.34, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for NGM to invest in growth at high rates of return.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Yung MD | Keros Therapeutics | 48 | |
| Leonard MD | C4 Therapeutics | 62 | |
| Stacy Rollinger | NextCure | N/A | |
| Edward Rebar | Sana Biotechnology | 56 | |
| John MD | Sana Biotechnology | N/A | |
| Sourav Kundu | NextCure | 63 | |
| Anuj MD | Assembly Biosciences | 46 | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| MS MBA | Rezolute | 50 | |
| Christopher Nasveschuk | C4 Therapeutics | N/A | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| JD Esq | Erasca Inc | 52 | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Jeffrey Fellows | Mineralys Therapeutics, Common | N/A | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Mayra ReyesArmour | C4 Therapeutics | N/A | |
| Douglas CPA | Century Therapeutics | N/A | |
| Michael Covarrubias | Rezolute | N/A | |
| Courtney Solberg | C4 Therapeutics | N/A | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| Neel Anand | Kezar Life Sciences | N/A | |
Management Performance
| Return On Equity | -0.7 | |||
| Return On Asset | -0.38 |
NGM Biopharmaceuticals Leadership Team
Elected by the shareholders, the NGM Biopharmaceutica's board of directors comprises two types of representatives: NGM Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NGM. The board's role is to monitor NGM Biopharmaceutica's management team and ensure that shareholders' interests are well served. NGM Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NGM Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony Kuhlmann, Head Property | ||
| Arthur Hsu, Senior Biology | ||
| David Woodhouse, CEO Director | ||
| Alex DePaoli, Chief VP | ||
| MD FACC, Chief VP | ||
| William JD, Executive Directors | ||
| Brian Muma, VP Operations | ||
| Daniel Kaplan, Chief Officer | ||
| Hsiao Lieu, Chief VP | ||
| Jean Viret, Chief Officer | ||
| Mahi Saraf, Director Culture | ||
| Jessica Ferreyra, Research Staff | ||
| Diana Bockus, Head Development | ||
| Siobhan Mangini, Principal Pres | ||
| Brian Schoelkopf, Sr IR | ||
| Valerie JD, General VP | ||
| Irene Perlich, Corporate VP | ||
| JinLong Chen, Chief Founder |
NGM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NGM Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.7 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (179.78) % | |||
| Current Valuation | (36.13 M) | |||
| Shares Outstanding | 83.46 M | |||
| Shares Owned By Insiders | 21.08 % | |||
| Shares Owned By Institutions | 54.16 % | |||
| Number Of Shares Shorted | 1.68 M | |||
| Price To Earning | (21.12) X | |||
| Price To Book | 0.86 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in NGM Stock
If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |